GlobeNewswire 12/11/2023 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 12/8/2023 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 12/6/2023 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 11/28/2023 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 11/20/2023 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
GlobeNewswire 11/7/2023 US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spher...
TeleTrader 10/24/2023 Novartis Q3 EPS up 20% to $0.73
GlobeNewswire 10/19/2023 Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search
GlobeNewswire 10/10/2023 Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
TeleTrader 10/4/2023 Sandoz seals spin-off from Novartis, starts trading
GlobeNewswire 9/22/2023 Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac...
TeleTrader 7/18/2023 Novartis' EPS jump 44% to $1.11 in Q2
TeleTrader 6/12/2023 Novartis to acquire Chinook Therapeutics in H2 2023
TeleTrader 4/25/2023 Novartis EPS up 9% to $1.09 in Q1
TeleTrader 3/27/2023 Novartis up 5% as breast cancer drug delivers upbeat results
TeleTrader 2/1/2023 Novartis' Q4 EPS down 91% to $0.69
TeleTrader 10/25/2022 Novartis' Q3 EPS tumbles 41% to $0.73
TeleTrader 7/19/2022 Novartis' EPS down 40% to $0.77 in Q2
TeleTrader 6/28/2022 Novartis to cut 1,400 jobs in Switzerland - report
TeleTrader 4/26/2022 Novartis Q1 sales up 5% to $12.53 billion
GlobeNewswire 3/17/2022 Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Nova...
GlobeNewswire 3/15/2022 Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire 3/8/2022 Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
GlobeNewswire 3/8/2022 Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to ...
TeleTrader 2/2/2022 Novartis' Q4 revenue hits expected $13.23 billion